Subtopic Deep Dive
Diffuse Large B-Cell Lymphoma Classification
Research Guide
What is Diffuse Large B-Cell Lymphoma Classification?
Diffuse Large B-Cell Lymphoma (DLBCL) classification divides this aggressive non-Hodgkin lymphoma into molecular subtypes like germinal center B-cell-like (GCB) and activated B-cell-like (ABC) using gene expression profiling and immunohistochemistry for prognosis and therapy selection.
Hans et al. (2003) confirmed GCB and ABC subtypes via tissue microarray immunohistochemistry, building on cDNA microarray profiles (4212 citations). WHO classifications evolved through 2008 (Campo et al., 1957 citations) and 2022 editions (Alaggio et al., 3291 citations), incorporating genomic mutations like those in histone-modifying genes (Morin et al., 2011, 1592 citations). Over 20,000 citations across key papers reflect subtype-driven diagnostic refinements.
Why It Matters
GCB and ABC DLBCL subtypes predict survival differences, with ABC showing poorer R-CHOP response (Hans et al., 2003). Morin et al. (2011) identified EZH2 and other mutations frequent in DLBCL, enabling targeted therapies. Alaggio et al. (2022) updated WHO criteria for precise categorization, improving immunotherapy selection like PD-1 ligands in amplified cases (Green et al., 2010). Accurate classification raises 5-year survival from 40% in ABC to 60% in GCB, guiding clinical trials.
Key Research Challenges
IHC Algorithm Variability
Immunohistochemical panels like Hans algorithm yield 80-90% concordance with gene expression but vary by antibody clones (Hans et al., 2003). Type 3 (unclassified) cases complicate prognosis. Standardization across labs remains inconsistent (Campo et al., 2011).
Genomic Heterogeneity Integration
Mutations in histone genes occur in 20-30% DLBCL but integration with IHC subtypes is incomplete (Morin et al., 2011). NGS reveals double-hit lymphomas missed by IHC. Alaggio et al. (2022) highlight need for multi-omics consensus.
Prognostic Subtype Refinement
ABC/GCB distinction loses power in relapsed DLBCL (Tilly et al., 2015). WHO 2022 adds high-grade categories but validation datasets are small. Green et al. (2010) note PD-L1 amplification overlaps subtypes, blurring boundaries.
Essential Papers
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans · 2003 · Blood · 4.2K citations
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles...
WHO-EORTC classification for cutaneous lymphomas
Rein Willemze · 2005 · Blood · 3.8K citations
Primary cutaneous lymphomas are currently classified by the European Organization for Research and Treatment of Cancer (EORTC) classification or the World Health Organization (WHO) classification, ...
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos et al. · 2022 · Leukemia · 3.3K citations
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elı́as Campo, Steven H. Swerdlow, Nancy L. Harris et al. · 2011 · Blood · 2.0K citations
Abstract The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of dist...
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin, María Méndez-Lago, Andrew J. Mungall et al. · 2011 · Nature · 1.6K citations
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgkin lymphomas (NHLs). Here we sequenced tumour and matched normal DNA from 13 DLBCL cases and one ...
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Rein Willemze, Lorenzo Cerroni, Werner Kempf et al. · 2019 · Blood · 1.3K citations
Abstract Primary cutaneous lymphomas are a heterogeneous group of T- and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. The 2005 Worl...
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green, Stefano Monti, Scott J. Rodig et al. · 2010 · Blood · 1.3K citations
Abstract Classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (MLBCL) are lymphoid malignancies with certain shared clinical, histologic, and molecular features. Primary cHLs and ...
Reading Guide
Foundational Papers
Read Hans (2003) first for IHC validation of GCB/ABC subtypes (4212 citations); Campo (2011) for 2008 WHO context (1957 citations); Morin (2011) for genomic basis (1592 citations).
Recent Advances
Alaggio (2022) for 5th WHO edition (3291 citations); Tilly (2015) for ESMO guidelines (893 citations); Willemze (2019) for cutaneous extensions (1301 citations).
Core Methods
IHC panels (CD10/BCL6/MUM1); gene expression microarrays; NGS for EZH2/CREBBP mutations; TMA for validation.
How PapersFlow Helps You Research Diffuse Large B-Cell Lymphoma Classification
Discover & Search
Research Agent uses searchPapers('DLBCL GCB ABC classification') to retrieve Hans (2003) with 4212 citations, then citationGraph reveals forward citations to Alaggio (2022). exaSearch on 'DLBCL IHC algorithm concordance' finds Campo (2011); findSimilarPapers expands to Morin (2011) mutations.
Analyze & Verify
Analysis Agent runs readPaperContent on Hans (2003) to extract IHC markers (CD10, BCL6, MUM1), verifies GCB/ABC survival curves via runPythonAnalysis (Kaplan-Meier plotting with pandas). CoVe chain-of-verification cross-checks mutation frequencies from Morin (2011) against Tilly (2015) guidelines; GRADE scores Hans algorithm as high-evidence for prognosis.
Synthesize & Write
Synthesis Agent detects gaps like unclassified type 3 DLBCL prognosis via contradiction flagging across Campo (2011) and Alaggio (2022). Writing Agent uses latexEditText for subtype table, latexSyncCitations integrates 10 papers, latexCompile generates review PDF; exportMermaid diagrams GCB/ABC pathways.
Use Cases
"Compare survival rates between GCB and ABC DLBCL subtypes from key studies."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (meta-analysis of Hans 2003 + Tilly 2015 Kaplan-Meier data) → outputs GRADE-verified survival plot with HR=0.6 for GCB.
"Draft LaTeX section on DLBCL WHO 2022 classification updates."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Alaggio 2022, Campo 2011) + latexCompile → researcher gets formatted PDF with cited subtype table.
"Find code for DLBCL gene expression subtype classifier."
Research Agent → paperExtractUrls (Morin 2011) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs Python scikit-learn classifier trained on GCB/ABC profiles.
Automated Workflows
Deep Research workflow scans 50+ DLBCL papers via searchPapers → citationGraph → structured report on subtype evolution from Hans (2003) to Alaggio (2022). DeepScan applies 7-step CoVe to verify IHC concordance claims, outputting GRADE table. Theorizer generates hypotheses on mutation-subtype links from Morin (2011) data.
Frequently Asked Questions
What defines GCB and ABC DLBCL subtypes?
GCB shows CD10+ or BCL6+ MUM1- IHC; ABC is CD10- BCL6- MUM1+ per Hans et al. (2003). Confirmed via cDNA microarray gene signatures.
What methods classify DLBCL?
IHC algorithms (Hans 2003), NGS for mutations (Morin 2011), WHO criteria (Alaggio 2022). TMA validates microarray profiles.
What are key papers?
Hans (2003, 4212 citations) for IHC confirmation; Alaggio (2022, 3291 citations) for WHO 5th edition; Morin (2011, 1592 citations) for mutations.
What open problems exist?
Type 3 unclassified cases (20%); integrating NGS with IHC; relapsed DLBCL subtype stability (Tilly 2015).
Research Lymphoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Diffuse Large B-Cell Lymphoma Classification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lymphoma Diagnosis and Treatment Research Guide